@misc{indiciae6ba6e55439e1,
  title = {PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine},
  author = {Arribas, A. J. and Gaudio, E. and Napoli, S. and Herbaux, C. J. and Tarantelli, C. and Bordone Pittau, R. and Cascione, L. and Munz, N. and Aresu, L. and Sgrignani, J. and Rinaldi, A. and Kwee, I. and Rossi, D. and Cavalli, A. and Zucca, E. and Stussi, G. and Stathis, A. and Sloss, C. and Davids, M. S. and Bertoni, F.},
  year = {2023},
  doi = {10.1101/2023.11.14.566994},
  url = {https://www.biorxiv.org/content/10.1101/2023.11.14.566994v1},
  note = {Source identifier: 10.1101/2023.11.14.566994}
}